Medscape is available in 5 Language Editions – Choose your Edition here.


Drug Eruptions

  • Author: Jonathan E Blume, MD; Chief Editor: Dirk M Elston, MD  more...
Updated: Aug 05, 2016

Practice Essentials

Drug eruptions can mimic a wide range of dermatoses. The morphologies are myriad and include morbilliform (see the image below), urticarial, papulosquamous, pustular, and bullous. Medications can also cause pruritus and dysesthesia without an obvious eruption. A drug-induced reaction should be considered in any patient who is taking medications and who suddenly develops a symmetric cutaneous eruption.

Morbilliform drug eruption. Morbilliform drug eruption.

Signs and symptoms

The first steps in the history are as follows:

  • Review the patient’s complete medication list, including prescription and over-the-counter drugs
  • Document any history of previous adverse reactions to drugs or foods
  • Consider alternative etiologies (eg, viral exanthems and bacterial infections)
  • Note any concurrent infections, metabolic disorders, or immunocompromise

In addition, the following should be noted and detailed:

  • Interval between introduction of a drug and onset of the eruption
  • Route, dose, duration, and frequency of drug administration
  • Use of parenterally administered drugs (more likely to cause anaphylaxis)
  • Use of topically applied drugs (more likely to induce delayed-type hypersensitivity)
  • Use of multiple courses of therapy and prolonged administration (risk of allergic sensitization)
  • Any improvement after drug withdrawal and any reaction with readministration

Physical examination should address clinical features that may indicate a severe, potentially life-threatening drug reaction, including the following:

  • Mucous membrane erosions
  • Blisters
  • Nikolsky sign
  • Confluent erythema
  • Angioedema and tongue swelling
  • Palpable purpura
  • Skin necrosis
  • Lymphadenopathy
  • High fever, dyspnea, or hypotension

It is important to appreciate the morphology and physical features of drug eruptions, as follows:

  • Acneiform
  • Acral erythema (erythrodysesthesia)
  • AGEP
  • Dermatomyositislike
  • Erythema multiforme (EM), including EM minor, SJS, TEN, and SJS/TEN overlap
  • Erythema nodosum
  • Erythroderma
  • Fixed drug eruptions
  • Hypersensitivity syndrome
  • Leukocytoclastic vasculitis
  • Lichenoid
  • Lupus
  • Morbilliform or exanthematous
  • Pseudoporphyria [1]
  • Serum sickness and serum sickness–like
  • Sweet syndrome (acute febrile neutrophilic dermatosis)
  • Urticaria
  • Vesiculobullous

See Clinical Presentation for more detail.


With mild asymptomatic eruptions, the history and physical examination are often sufficient for diagnosis; with severe or persistent eruptions, further diagnostic testing may be required, as follows:

  • Biopsy
  • Complete blood count (CBC) with differential
  • Serum chemistry studies (especially for electrolyte balance and indices of renal or hepatic function in patients with severe reactions)
  • Antibody or immunoserology tests
  • Direct cultures to investigate a primary infectious etiology or secondary infection
  • Urinalysis, stool guaiac tests, and chest radiography for vasculitis
  • Skin prick or patch testing to confirm the causative agent

See Workup for more detail.


Principles of medical care are as follows:

  • The ultimate goal is to identify and discontinue the offending medication if possible
  • Patients can sometimes continue to be treated through morbilliform eruptions; nevertheless, all patients with severe morbilliform eruptions should be monitored for mucous membrane lesions, blistering, and skin sloughing
  • Treatment of a drug eruption depends on the specific type of reaction
  • Therapy for exanthematous drug eruptions is supportive, involving the administration of oral antihistamines, topical steroids, and moisturizing lotions
  • Severe reactions (eg, SJS, TEN, and hypersensitivity reactions) warrant hospital admission
  • TEN is best managed in a burn unit, and intravenous immunoglobulin (IVIG) may improve outcomes [2, 3, 4]
  • Hypersensitivity syndrome may have to be treated with liver transplantation if the offending drug is not stopped in time; treatment with systemic corticosteroids has been advocated in the acute phase; in the chronic phase, patients may require treatment for hypothyroidism or diabetes mellitus

For most drug eruptions, full recovery without any complications is expected; however, the following should be noted:

  • Patients with exanthematous eruptions should expect mild desquamation as the rash resolves
  • Patients with hypersensitivity syndrome are at risk of becoming hypothyroid, usually within the first 4-12 weeks after the reaction; there is also a risk of diabetes
  • The prognosis for patients with TEN is guarded; scarring, blindness, and death are possible

See Treatment and Medication for more detail.



Drug eruptions can mimic a wide range of dermatoses. The morphologies are myriad and include morbilliform (most common, see image below), urticarial, papulosquamous, pustular, and bullous. Medications can also cause pruritus and dysesthesia without an obvious eruption. Both calcium channel blockers and interferon are strongly associated with eczematous eruptions.

Morbilliform drug eruption. Morbilliform drug eruption.

A drug-induced reaction should be considered in any patient who is taking medications and who suddenly develops a symmetric cutaneous eruption. Medications that are known for causing cutaneous reactions include antimicrobial agents,[5] nonsteroidal anti-inflammatory drugs (NSAIDs), cytokines, chemotherapeutic agents, anticonvulsants, and psychotropic agents.

Prompt identification and withdrawal of the offending agent may help limit the toxic effects associated with the drug. The decision to discontinue a potentially vital drug often presents a dilemma.



Drug eruptions may be divided into immunologically and nonimmunologically mediated reactions.

Immunologically mediated reactions

Coombs and Gell proposed four types of immunologically mediated reactions, as follows:

  • Type I is immunoglobulin E (IgE)–dependent reactions, which result in urticaria, angioedema, and anaphylaxis (see the image below).
    Urticaria. Urticaria.
  • Type II is cytotoxic reactions, which result in hemolysis and purpura (see the image below).
    Oral ulcerations in a patient receiving cytotoxic Oral ulcerations in a patient receiving cytotoxic therapy.
  • Type III is immune complex reactions, which result in vasculitis, serum sickness, and urticaria.
  • Type IV is delayed-type reactions with cell-mediated hypersensitivity, which result in contact dermatitis, exanthematous reactions, and photoallergic reactions.

Th17 T cells are implicated in many drug eruptions, and sulfamethoxazole induces a T-cell switch mechanism based on the TCRVβ20-1 domain altering peptide-HLA recognition. In severe drug reactions, micro RNA-18a-5p down-regulates the expression of the antiapoptotic B-cell lymphoma/leukemia-2–like protein 10 (BCL2L10), promoting apoptosis.

Insulin and other proteins are associated with type I reactions. Penicillin, cephalosporins, sulfonamides, and rifampin are known to cause type II reactions. Quinine, salicylates, chlorpromazine, and sulfonamides can cause type III reactions. Type IV reactions, the most common mechanism of drug eruptions, are often encountered in cases of contact hypersensitivity to topical medications, such as neomycin. Sulfonamides are most frequently associated with toxic epidermal necrolysis (TEN).

Although most drug eruptions are type IV hypersensitivity reactions, only a minority are IgE-dependent. That is, antibodies can be demonstrated in less than 5% of cutaneous drug reactions. Type IV cell-mediated reactions are not dose dependent, they usually begin 7-20 days after the medication is started, they may involve blood or tissue eosinophilia, and they may recur if drugs chemically related to the causative agent are administered.

Nonimmunologically mediated reactions

Nonimmunologically mediated reactions may be classified according to the following features: accumulation, adverse effects, direct release of mast cell mediators, idiosyncratic reactions, intolerance, Jarisch-Herxheimer phenomenon, overdosage, or phototoxic dermatitis. (Symptoms of Jarisch-Herxheimer reactions disappear with continued therapy. Drug therapy should be continued until the infection is fully eradicated.)

An example of accumulation is argyria (blue-gray discoloration of skin and nails) observed with use of silver nitrate nasal sprays.

Adverse effects are normal but unwanted effects of a drug. For example, antimetabolite chemotherapeutic agents, such as cyclophosphamide, are associated with hair loss.

The direct release of mast cell mediators is a dose-dependent phenomenon that does not involve antibodies. For example, aspirin and other NSAIDs cause a shift in leukotriene production, which triggers the release of histamine and other mast-cell mediators. Radiographic contrast material, alcohol, cytokines, opiates, cimetidine, quinine, hydralazine, atropine, vancomycin, and tubocurarine also may cause release of mast-cell mediators.

Idiosyncratic reactions are unpredictable and not explained by the pharmacologic properties of the drug. An example is the individual with infectious mononucleosis who develops a rash when given ampicillin.

Imbalance of endogenous flora may occur when antimicrobial agents preferentially suppress the growth of one species of microbe, allowing other species to grow vigorously. For example, candidiasis frequently occurs with antibiotic therapy.

Intolerance may occur in patients with altered metabolism. For example, individuals who are slow acetylators of the enzyme N -acetyltransferase are more likely than others to develop drug-induced lupus in response to procainamide.

Jarisch-Herxheimer phenomenon is a reaction due to bacterial endotoxins and microbial antigens that are liberated by the destruction of microorganisms. The reaction is characterized by fever, tender lymphadenopathy, arthralgias, transient macular or urticarial eruptions, and exacerbation of preexisting cutaneous lesions. The reaction is not an indication to stop treatment because symptoms resolve with continued therapy. This reaction can be seen with penicillin therapy for syphilis, griseofulvin or ketoconazole therapy for dermatophyte infections, and diethylcarbamazine therapy for oncocerciasis.

Overdosage is an exaggerated response to an increased amount of a medication. For example, increased doses of anticoagulants may result in purpura.

Phototoxic dermatitis is an exaggerated sunburn response caused by the formation of toxic photoproducts, such as free radicals or reactive oxygen species (see the image below).

Phototoxic reaction after use of a tanning booth. Phototoxic reaction after use of a tanning booth. Note sharp cutoff where clothing blocked exposure.


United States

Drug eruptions occur in approximately 2-5% of inpatients and in greater than 1% of outpatients.


Drug eruptions occur in approximately 2-3% of inpatients.


Adverse cutaneous reactions to drugs are more prevalent in women than in men.


Elderly patients have an increased prevalence of adverse drug reactions.



Most drug eruptions are mild, self-limited, and usually resolve after the offending agent has been discontinued. Even after the responsible agent is discontinued, drug eruptions may clear slowly or worsen over the next few days. The degree of eosinophilia is predictive of the severity of the drug eruption.[6, 7] The time required for total clearing may be 1-2 weeks or longer.

Severe and potentially life-threatening eruptions occur in approximately 1 in 1000 hospital patients. Mortality rates for erythema multiforme (EM) major are significantly higher. Stevens-Johnson syndrome (SJS) has a mortality rate of less than 5%, whereas the rate for TEN approaches 20-30%; most patients die from sepsis.

Patients with exanthematous eruptions should be counseled to expect mild desquamation as the rash resolves.

Patients with hypersensitivity syndrome are at risk of becoming hypothyroid, usually within the first 4-12 weeks after the reaction.

The prognosis for patients with TEN is guarded. Scarring, blindness, and death are possible.


Patient Education

If the responsible drug is identified, advise the patient to avoid that drug in the future. Clearly label the medical record. Advise patients to carry a card or some other form of emergency identification in their wallets that lists drug allergies and/or intolerances, especially if they have had a severe reaction.

Advise patients about drugs that are cross-reactive and about drugs that must be avoided. For example, penicillin allergy reactions have cross-reactivity with cephalosporins, phenytoin hypersensitivity syndrome has cross-reactivity with phenobarbital and carbamazepine, and sulfonamide reactions cross-react with other sulfa-containing drugs.

For patient education resources, see the Allergy Center.

Contributor Information and Disclosures

Jonathan E Blume, MD Instructor in Clinical Dermatology, Columbia University College of Physicians and Surgeons; Dermatologist, Westwood Dermatology and Dermatologic Surgery Group PA

Jonathan E Blume, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, International Society of Dermatology

Disclosure: Nothing to disclose.


Michelle Ehrlich, MD Director of Cosmetic Dermatology and Surgery Residency Program, Harbor-UCLA Medical Center; Clinical Instructor, Department of Dermatology, University of California, Los Angeles, David Geffen School of Medicine

Michelle Ehrlich, MD is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Dermatology

Disclosure: Nothing to disclose.

Thomas N Helm, MD Clinical Professor of Dermatology and Pathology, University of Buffalo, State University of New York School of Medicine and Biomedical Sciences; Director, Buffalo Medical Group Dermatopathology Laboratory

Thomas N Helm, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society for Dermatologic Surgery, American Society of Dermatopathology

Disclosure: Nothing to disclose.

Liaqat Ali, MD Assistant Professor, Department of Dermatology, Wayne State University School of Medicine; Dermatopathologist, Pinkus Dermatopathology Laboratory, Monroe, MI

Liaqat Ali, MD is a member of the following medical societies: American Society for Clinical Pathology, American Society of Dermatopathology, College of American Pathologists, United States and Canadian Academy of Pathology

Disclosure: Nothing to disclose.

Specialty Editor Board

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, American College of Rheumatology

Disclosure: Received income in an amount equal to or greater than $250 from: XOMA; Biogen/IDEC; Novartis; Janssen Biotech, Abbvie, CSL pharma<br/>Received honoraria from UpToDate for author/editor; Received honoraria from JAMA Dermatology for associate editor and intermittent author; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for i inherited these trust accounts; for: Celgene; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble; Amgen.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Neil Shear, MD Professor and Chief of Dermatology, Professor of Medicine, Pediatrics and Pharmacology, University of Toronto Faculty of Medicine; Head of Dermatology, Sunnybrook Women's College Health Sciences Center and Women's College Hospital, Canada

Neil Shear, MD is a member of the following medical societies: Canadian Medical Association, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada, Canadian Dermatology Association, American Academy of Dermatology, American Society for Clinical Pharmacology and Therapeutics

Disclosure: Nothing to disclose.


Charles Camisa, MD Head of Clinical Dermatology, Vice-Chair, Department of Dermatology, Cleveland Clinic Foundation

Charles Camisa, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

  1. Green JJ, Manders SM. Pseudoporphyria. J Am Acad Dermatol. 2001 Jan. 44(1):100-8. [Medline].

  2. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol. 2006 Apr. 6(4):543-9. [Medline].

  3. Mukasa Y, Craven N. Management of toxic epidermal necrolysis and related syndromes. Postgrad Med J. 2008 Feb. 84(988):60-5. [Medline].

  4. Paquet P, Pierard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol. 2005 Mar. 136(3):205-16. [Medline].

  5. Iannini P, Mandell L, Felmingham J, Patou G, Tillotson GS. Adverse cutaneous reactions and drugs: a focus on antimicrobials. J Chemother. 2006 Apr. 18(2):127-39. [Medline].

  6. Walsh S, Diaz-Cano S, Higgins E, Morris-Jones R, Bashir S, Bernal W, et al. Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. Br J Dermatol. 2013 Feb. 168(2):391-401. [Medline].

  7. Yang J, Yang X, Li M. Peripheral blood eosinophil counts predict the prognosis of drug eruptions. J Investig Allergol Clin Immunol. 2013. 23(4):248-55. [Medline].

  8. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993 Jun 10. 328(23):1670-4. [Medline].

  9. Taddio A, Lee CM, Parvez B, Koren G, Shah V. Contact dermatitis and bradycardia in a preterm infant given tetracaine 4% gel. Ther Drug Monit. 2006 Jun; 28(3):291-4. Available at

  10. Thakor P, Padmanabhan M, Johnson A, Pararajasingam T, Thakor S, Jorgensen W. Ramipril-induced generalized pustular psoriasis: case report and literature review. Available at

  11. Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol. 2003 Mar. 48(3):439-41. [Medline].

  12. Nofal A, El-Din ES. Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption?. Int J Dermatol. 2012 May. 51(5):535-41. [Medline].

  13. Shaughnessy KK, Bouchard SM, Mohr MR, Herre JM, Salkey KS. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol. 2010 Feb; 62 (2):315-8. Available at

  14. Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol. 1998 May-Jun. 16(3):325-32. [Medline].

  15. Camilleri M, Pace JL. Drug-induced linear immunoglobulin-A bullous dermatosis. Clin Dermatol. 1998 May-Jun. 16(3):389-91. [Medline].

  16. Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N. Drug-induced lupus erythematosus. Clin Dermatol. 2004 Mar-Apr. 22(2):157-66. [Medline].

  17. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol. 1998 May-Jun. 16(3):393-7. [Medline].

  18. Brauchli YB, Jick SS, Curtin F, Meier CR. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br J Dermatol. 2008 Jun. 158(6):1299-307. [Medline].

  19. Dika E, Varotti C, Bardazzi F, Maibach HI. Drug-induced psoriasis: an evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutan Ocul Toxicol. 2006. 25(1):1-11. [Medline].

  20. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. 2000 May-Jun. 1(3):159-65. [Medline].

  21. Clark BM, Kotti GH, Shah AD, Conger NG. Severe serum sickness reaction to oral and intramuscular penicillin. Pharmacotherapy. 2006 May. 26(5):705-8. [Medline].

  22. Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med. 2008. 40(2):129-38. [Medline].

  23. Lee HY, Pang SM, Thamotharampillai T. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2008 Aug. 59(2):352-3. [Medline].

  24. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995 Dec 14. 333(24):1600-7. [Medline].

  25. Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant. 2012 Apr 6. [Medline].

  26. Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol. 2010 Mar. 146(3):300-4. [Medline].

  27. MacMorran WS, Krahn LE. Adverse cutaneous reactions to psychotropic drugs. Psychosomatics. 1997 Sep-Oct. 38(5):413-22. [Medline].

  28. Roe E, Garcia Muret MP, Marcuello E, Capdevila J, Pallares C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol. 2006 Sep. 55(3):429-37. [Medline].

  29. Graves JE, Jones BF, Lind AC, Heffernan MP. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol. 2006 Aug. 55(2):349-53. [Medline].

  30. Donovan JC, Ghazarian DM, Shaw JC. Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib. Arch Dermatol. 2008 Nov. 144(11):1524-5. [Medline].

  31. Shipley D, Ormerod AD. Drug-induced urticaria. Recognition and treatment. Am J Clin Dermatol. 2001. 2(3):151-8. [Medline].

  32. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol. 2008 Apr. 58(4):545-70. [Medline].

  33. Wu PA, Balagula Y, Lacouture ME, Anadkat MJ. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr Opin Oncol. 2011 Jul. 23(4):343-51. [Medline].

  34. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Medline. Available at

  35. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23. 366(8):707-14. [Medline].

  36. Harding JJ, Pulitzer M, Chapman PB. Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med. 2012 Mar 1. 366(9):866-8. [Medline].

  37. Teoh DC, Aw DC, Jaffar H, et al. Tamoxifen-induced eccrine squamous syringometaplasia. J Cutan Pathol. 2012 May. 39(5):554-7. [Medline].

  38. Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol. 1995 Sep. 33(3):393-410; quiz 410-2. [Medline].

  39. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012 May. 39(5):481-92. [Medline].

  40. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Medline. Available at

  41. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005 Apr 15. 209(2):209-16. [Medline].

  42. Aquino MR, Sher J, Fonacier L. Patch testing for drugs. Dermatitis. 2013 Sep-Oct. 24(5):205-14. [Medline].

  43. Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013 Mar. 168(3):555-562. [Medline].

  44. Campos-Fernandez Mdel M, Ponce-De-Leon-Rosales S, Archer-Dubon C, Orozco-Topete R. Incidence and risk factors for cutaneous adverse drug reactions in an intensive care unit. Rev Invest Clin. 2005 Nov-Dec. 57(6):770-4. [Medline].

  45. Chen CJ, Cheng CF, Lin HY, Hung SP, Chen WC, Lin MS. A comprehensive 4-year survey of adverse drug reactions using a network-based hospital system. J Clin Pharm Ther. 2012 Dec. 37(6):647-51. [Medline].

  46. Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. Clin Aspects Immunol. 1968. 575-96.

  47. de la Torre C, Suh Oh HJ. Advances in the diagnosis of drug eruptions. Actas Dermosifiliogr. 2013 Nov. 104(9):782-8. [Medline].

  48. Gendernalik SB, Galeckas KJ. Fixed drug eruptions: a case report and review of the literature. Cutis. 2009 Oct. 84(4):215-9. [Medline].

  49. Greenberger PA. 8. Drug allergy. J Allergy Clin Immunol. 2006 Feb. 117(2 Suppl Mini-Primer):S464-70. [Medline].

  50. Heelan K, Shear NH. Cutaneous drug reactions in children: an update. Paediatr Drugs. 2013 Dec. 15(6):493-503. [Medline].

  51. Mayorga C, Pena RR, Blanca-Lopez N, Lopez S, Martin E, Torres MJ. Monitoring the acute phase response in non-immediate allergic drug reactions. Curr Opin Allergy Clin Immunol. 2006 Aug. 6(4):249-57. [Medline].

  52. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007 Feb. 56(2):181-200. [Medline].

  53. Sahin S, Comert A, Akin O, Ayalp S, Karsidag S. Cutaneous drug eruptions by current antiepileptics: case reports and alternative treatment options. Clin Neuropharmacol. 2008 Mar-Apr. 31(2):93-6. [Medline].

  54. Seitz CS, Rose C, Kerstan A, Trautmann A. Drug-induced exanthems: correlation of allergy testing with histologic diagnosis. J Am Acad Dermatol. 2013 Nov. 69(5):721-8. [Medline].

  55. Summers EM, Bingham CS, Dahle KW, Sweeney C, Ying J, Sontheimer RD. Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers. JAMA Dermatol. 2013 Jul. 149(7):814-8. [Medline].

  56. Turk BG, Gunaydin A, Ertam I, Ozturk G. Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan Ocul Toxicol. 2013 Mar. 32(1):41-5. [Medline].

  57. Ward KE, Archambault R, Mersfelder TL. Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature. Am J Health Syst Pharm. 2010 Feb 1. 67(3):206-13. [Medline].

  58. Wolf R, Orion E, Marcos B, Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol. 2005 Mar-Apr. 23(2):171-81. [Medline].

  59. Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol. 2006. 7(1):45-63. [Medline].

Morbilliform drug eruption.
Warfarin (Coumadin) necrosis involving the leg.
Toxic epidermal necrolysis.
Stevens-Johnson syndrome.
Erythema multiforme.
Fixed drug eruption.
Fixed drug eruption involving the penis.
Oral ulcerations in a patient receiving cytotoxic therapy.
Phototoxic reaction after use of a tanning booth. Note sharp cutoff where clothing blocked exposure.
Vasculitic reaction on the legs.
Lichen planus on the neck.
Steroid acne. Note pustules and absence of comedones.
Drug reaction to hydroxychloroquine (Plaquenil).
Erythema nodosum.
Confluent necrosis of the epidermis in toxic epidermal necrolysis.
Perivascular mixed inflammatory infiltrate with eosinophils characteristic of drug-induced urticaria.
Biopsy of pseudoporphyria shows a subepidermal blister with little to no inflammation.
Confluent necrosis of the epidermis in toxic epidermal necrolysis.
Superficial perivascular inflammatory infiltrate with numerous eosinophils characteristic of an exanthematous drug eruption.
Target lesions of erythema multiforme.
Papules and annular plaques.
Superficial and mid-dermal perivascular infiltrate of lymphocytes and eosinophils. Foci of extravasation of erythrocytes.
Numerous milia in a patient treated with vemurafenib.
Dilated infundibular cyst.
Male-pattern diffuse hair loss.
Pink/fleshy perifollicular papules with diffuse alopecia.
Horizontal section shows perifollicular fibrosis consistent with scarring alopecia.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.